Abstract 1 -- Beyond PARP1: Ribosylation as a Target for Cancer Therapy
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Poly (ADP‐ribose) polymerase (PARP) proteins play important roles in regulating stress responses that enable cancer cell survival, and thus inhibition of PARP activity provides a new approach to treat cancer by blocking these survival pathways. PARPs constitute a family of 17 enzymes that alter the function of target proteins by catalyzing the transfer of ADP‐ribose from NAD+ to protein substrates. The PARP family is divided into two major subfamilies (polyPARPs and monoPARPs) based upon the production of either poly (ADP‐ribosylated) or mono (ADP‐ribosylated) proteins, respectively. In addition, one family member, PARP13, has been reported to be catalytically inactive. Much of the attention on the PARP family has been focused on the polyPARP PARP1, and inhibitors targeting PARP1 have been approved for the treatment of cancer. Data are emerging regarding the role of the monoPARPs distinct from PARP1. The specific substrates and functions of the twelve monoPARP proteins are currently being elucidated, and these recent discoveries indicate that several monoPARPs, including PARP7, play important roles in cancer survival pathways. PARP7 is genetically amplified in several cancers, including squamous cell carcinoma of the lung, and amplification correlates with high expression in these tumors. PARP7 blocks pattern recognition receptor signaling, resulting in inhibition of interferon signaling and immunosuppression. PARP7 inhibition results in restoration of interferon signaling and blocks tumor growth in mice. PARP7 is a novel therapeutic target in cancers, including squamous cell carcinoma of the lung.

Abstract 2 -- Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis
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Cutaneous melanoma is among the few cancers with a well‐documented carcinogenic etiology (UV) yet with unrelenting increases in incidence. The melanoma genome typically contains thousands of UV‐signature mutations. Many of these lack oncogenic driver activity but are recognized to contribute to immune recognition as potential neoantigens. This presentation will explore features of cutaneous adaptation to sun/UV that suggest a powerful set of mechanisms that balance evolutionary requirements for UV (i.e., vitamin D) against tissue injury inflicted by UV. Carcinogenic features of red/blond pigment will be discussed, as well as manipulation of skin pigmentation and behavioral signals triggered by UV exposure. Despite the high mutational load of melanoma, the majority of patients fail to achieve durable clinical benefit from current immune checkpoint therapies. A genetically defined murine cancer model will be presented that enables dissection of the role(s) for UV neoantigens in immunotherapy responses and has permitted the development of novel approaches to "rescue" immunotherapy responsiveness in tumors that are deficient in neoantigens or pre‐existing tumor inflammation.

Abstract 3 -- Targeting Cell Death Pathways with Precision Using Functional Assays
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The mitochondrial pathway of apoptosis is probably the mechanism of death in the majority of cases of response of tumors to chemotherapy. For many years, my laboratory has used a tool, BH3 profiling, to measure how close a cell is to the threshold of commitment to apoptosis. We call this being "primed" for apoptosis. Our work suggests that how primed a cell is for apoptosis is a very important determinant for response to chemotherapy. In fact, it is probably the most important factor in determining sensitivity to conventional chemotherapy regimens. Moreover, it is likely the most important reason that there is a therapeutic index for the ubiquitously toxic DNA and microtubule poisons we rely on for cure in cancer chemotherapy. BH3 profiling can also interrogate the mitochondrial apoptotic pathway to reveal cancer dependence on individual anti‐apoptotic proteins, such as BCL‐2 or MCL‐1. We have used this application to assign BCL‐2 inhibitors like venetoclax to successful clinical trial programs in diseases, such as chronic lymphocytic leukemia and acute myelogenous leukemia. More recently, we have been using BH3 profiling to measure changes in apoptotic priming caused by short‐term exposures of drugs to cancer cells. We have found these measurements to be excellent predictors of the efficacy of drugs in vivo. Because these death signals are turned on in less than 24 hours in most cases, we do not require long‐term ex vivo culture and hence can apply our strategy directly to almost any primary cancer tissue sample. We think that such functional testing of anti‐cancer agents will be an increasingly important tool in matching patients to the drugs that most benefit them, which is the job that cancer precision medicine is supposed to perform.

Abstract 4 -- Digital RNA‐based Analysis of Circulating Tumor Cells for Noninvasive Monitoring of Cancer

Haber

Daniel A.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

Circulating tumor cells (CTCs) are shed from primary and metastatic tumors into the blood circulation, where they may provide a noninvasive measurement for either early cancer detection or serial monitoring of therapy. Analyses of rare CTCs have been hampered by technological hurdles in their enrichment and in their microscopic imaging. We previously described a microfluidic device, now automated, enabling high throughput depletion of normal hematopoietic cells from blood specimens, yielding a cell population enriched for viable CTCs with intact RNA. We have now applied an RNA‐based digital droplet‐PCR platform to provide high throughput and sensitive and specific CTC quantitation without the need for advanced microscopy. The use of lineage‐based transcripts to identify CTCs within the background of normal blood cells relies on multiple shared markers within individual tumor types to overcome heterogeneity in expression, and it does not require preexisting knowledge of primary tumor mutation profile. We will present initial proof of concept applications of this CTC‐score analysis for early detection of hepatocellular cancer among patients with underlying chronic liver disease, stratification of metastatic prostate cancer patients with poor response to anti‐androgen therapy, demonstration of early response of melanoma patients to immune checkpoint inhibitors, and monitoring drug‐induced changes in estrogen signaling in women with advanced breast cancer. Together, these analyses highlight potential clinical applications of RNA‐based liquid biopsy measurements in the care of patients with cancer.

Abstract 5 -- Clinical Application of Liquid Biopsies and Genotype‐Directed Targeted Therapies for Metastatic Breast Cancer
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Endocrine therapies, including aromatase inhibitors, represent the backbone of management of estrogen receptor positive (ER+) breast cancer. However, despite endocrine therapy, a number of patients with ER+ breast cancer experience disease recurrence, likely related to the development of primary and secondary resistance to endocrine therapy. Our group, along with others, has demonstrated the presence of acquired mutations in the ligand binding domain of estrogen receptor (ESR1), which can lead to constitutional activation of the estrogen receptor in the absence of ligand (estrogen) and thereby result in resistance to endocrine therapies. In addition, other acquired mutations have recently been identified based on molecular genotyping from liquid biopsies. These points, as well as clinical development of genotype‐directed targeted therapies for patients with metastatic breast cancer, will be reviewed.

Abstract 6 -- Microfluidics for the Characterization of Tumor‐Specific Extracellular Vesicles

Stott

Shannon

Massachusetts General Hospital, Boston, Massachusetts, USA

Extracellular vesicles (EVs) are lipid vesicles present in blood and other biofluids. These small particles vary from 50 nm to a few microns in size and carry rich biological cargo that includes proteins, mRNA, microRNA, and DNA. Through their content, EVs (sometimes referred to as exosomes) preserve the transcriptome information of their parent cells and provide unique opportunities for the development of cancer diagnostic tools. However, EVs have not seen widespread clinical testing due to limitations in isolation technologies that suffer from low throughput or lack of tumor specificity. To address this, we have developed a microfluidic platform, the EVHB‐Chip, for tumor‐specific recovery of EVs using immunoaffinity capture. Clinically, there is a dire need to diagnose and monitor brain tumor recurrence and to detect mutations in real time in glioblastoma, a highly fatal disease. Through this blood‐on‐a‐chip assay, we aim to gain a better understanding of when these important tumor‐derived vesicles are released and how we can exploit their molecular content to better guide patient treatment. Data will be presented on our technological approach, as well as our effort to interrogate the molecular content using next‐generation RNA sequencing and droplet digital PCR. Through the microfluidic isolation of blood‐based biomarkers from glioblastoma patients, our goal is to obtain complementary data to the current standard of care to better guide treatment.

Abstract 7 -- CAR T‐Cell Therapy for Ovarian Cancer
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Solid tumor malignancies have yet to benefit from chimeric antigen receptor (CAR) T‐cell therapy compared with hematologic malignancies, such as B‐cell acute lymphocytic leukemia and multiple myeloma. Despite initially promising preclinical data, early clinical trials in ovarian cancer have not yielded meaningful results. It is now accepted that the solid tumor microenvironment, which includes immunosuppressive immune cells, stromal cells, and cytokines, contributes to active determent of effective T‐cell activity. We sought to develop strategies to improve CAR T‐cell potency and overcome the hostile tumor microenvironment in ovarian cancer. Using CAR T‐cells directed to the retained portion of the MUC16 tumor‐associated antigen, we designed and evaluated armored CAR T‐cells secreting IL‐12 or anti‐PD‐1. IL‐12 armored CAR T‐cells displayed significant in vitro cytotoxicity and superior in vivo activity in a syngeneic mouse model of ovarian peritoneal carcinomatosis. These modified CAR T‐cells functioned via autocrine IL‐12 receptor stimulation, overcame PD‐L1‐mediated inhibition, and positively modulated the tumor microenvironment in vivo. This was partly mediated via deletion of tumor‐associated macrophages. Anti‐PD‐1‐secreting CAR T‐cells prolonged survival in both syngeneic and xenograft models of metastatic ovarian cancer. Furthermore, long‐term survivors showed CAR T‐cell persistence in the bone marrow and were able to resist a second round of tumor inoculation. We found that the secreted anti‐PD‐1 was contained in the tumor microenvironment and promoted anti‐tumor bystander effects in non‐armored and endogenous T‐cells. In summary, we have validated two alternative approaches to improving the efficacy of CAR T‐cells for ovarian cancer.

Abstract 8 -- Molecular Tumor Board: Resistance to Checkpoint Inhibitors
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The emergence of immune checkpoint inhibitors for the treatment of solid tumor malignancies has transformed the treatment of several diseases, including melanoma, renal cell carcinoma, urothelial bladder cancer, non‐small cell lung cancer, and many others. While these agents may be associated with remarkable responses that may be complete and durable, most patients will not respond to therapy, and a significant minority of patients who do respond will develop disease progression. An understanding of the underlying mechanisms of resistance to therapy is emerging. The objectives of this session will be to review the clinical data supporting the use of immune checkpoint inhibitors in melanoma as a test case, review specific cases of intrinsic and acquired resistance, describe the known mechanisms of resistance, and propose potential therapies to overcome therapeutic resistance.

Abstract 9 -- Dissecting Response and Resistance to Immune Checkpoint Blockade
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The development of immune checkpoint blockade (ICB) has revolutionized the treatment of cancer. However, most patients will develop resistance to therapy, and understanding how resistance evolves in tumors is critical to improving patient management and outcomes.

Here, we present an in‐depth phylogenetic analysis of a metastatic melanoma patient with delayed but exceptional response to sequential nivolumab‐ipilimumab ICB therapy who subsequently developed isolated escape lesions more than 3 years after therapy. We analyzed whole‐exome sequencing of 21 tumors and matched normal samples taken from pre‐treatment, on‐treatment, and post‐resistance time points to examine the development of clinical resistance. Phylogenetic analysis classified tumors into five distinct preexisting lineages at ICB initiation sharing a common ancestor with IDH1 and MAP2K1 driver mutations. We identified genomic alterations associated with ICB resistance in different lineages, including PTEN and B2M‐loss, alterations in cell cycle genes, and genomic aneuploidy associated with genome doubling. Post‐treatment resistant lesions arose out of a specific lineage with B2M deletion but acquired additional genomic alterations, including genome doubling and CDKN2A loss, compared with pre‐recurrence lesions in the same lineage.

This case demonstrates the heterogeneity of disease and establishes a high‐resolution map of the evolutionary dynamics of clinical resistance within an individual patient. The immune‐tumor interface is a complex balance, and our study suggests that resistant lesions may require accumulation of multiple escape mechanisms. Broadly, our study suggests that in‐depth analysis of individual patients with multiple tumors collected across time and treatment may illuminate the landscape of clinical evolution of ICB resistance.

Abstract 10 -- The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
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Breast cancer is the most common cancer among women in the United States, and the vast majority of patients present with early‐stage disease without clinical or radiologic evidence of metastatic disease. Among localized breast cancer, patients undergoing neoadjuvant (pre‐surgery) therapy represent an inherently high‐risk population. In addition to allowing earlier initiation of systemic therapy and the potential to improve the rate of breast conservation surgery, the neoadjuvant approach offers several research advantages. The neoadjuvant setting has become recognized as a human in vivo system to explore predictive biomarkers, surrogate endpoints, and the efficacy of therapies, including novel agents. Despite the advantages offered by the neoadjuvant approach, validated biomarkers to monitor early response to therapy do not exist. For example, both neoadjuvant chemotherapy and neoadjuvant endocrine therapy are potential treatments for locally advanced hormone receptor‐positive breast cancer, and a sensitive marker of early treatment response could help identify those patients who would do well with endocrine therapy alone, thereby avoiding cytotoxic chemotherapy. We are exploring predictors of response and resistance to neoadjuvant therapies, including the use of blood‐based biomarkers such as circulating tumor cells and circulating tumor DNA. If validated in the neoadjuvant setting, this approach could provide an important opportunity to individualize therapy, thereby minimizing unnecessary systemic toxicity associated with ineffective therapies, and could ultimately improve clinical outcomes.

Abstract 11 -- Clinical Utility of Longitudinal Molecular Profiling for Management of
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Multiple tyrosine kinase inhibitors (TKIs) are approved for treatment of advanced *ALK*‐positive non‐small cell lung cancer. Recent work has established second‐generation *ALK* TKIs as the preferred first‐line treatment approach. Despite durable responses, patients invariably relapse on these therapies. To date, analysis of biopsies from progressive lesions has been the primary method of characterizing resistance to *ALK* TKIs. These analyses have identified acquired *ALK* resistance mutations in more than half of patients relapsing on a second‐generation TKI. The spectrum of *ALK* resistance mutations is distinct for each *ALK* TKI, allowing a small subset of patients to respond to another second‐generation TKI. In general, however, treatment with a more potent broad‐spectrum third‐generation *ALK* TKI is the most effective way to salvage responses when resistance results from secondary *ALK* mutations. Recent data suggest that patients who relapse due to *ALK* resistance mutations benefit most from treatment with third‐generation *ALK* TKIs. However, there is variability in the magnitude of benefit among patients with tumors harboring identical *ALK* mutations. This suggests that single site tissue sampling does not adequately capture the extent of heterogeneity. As a readout of the molecular makeup of multiple sites, plasma genotyping is potentially better suited for dissecting the complex *ALK* resistance landscape. In this lecture, I will review the molecular basis of acquired resistance to next‐generation *ALK* TKIs, discuss the impact of heterogeneity on response to *ALK* therapies, demonstrate that plasma genotyping reliably detects *ALK* resistance mutations, and present emerging data supporting the potential for liquid biopsies to refine current understanding of determinants of *ALK* TKI response.

Abstract 12 -- New Biomarkers in a Novel Antibody‐Drug Conjugate for Triple‐Negative Breast Cancer
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Triple negative breast cancer (TNBC), defined by the lack of hormone receptors and the absence of HER2 overexpression, represents 15% to 20% of all breast cancers and has heterogeneous biology with poor prognosis. There is no approved targeted therapy for TNBC, which calls for a better treatment option. A novel antibody‐drug conjugate, sacituzumab govitecan (IMMU‐132), is a compound that conjugates an anti‐Trop‐2 antibody with the cytotoxic payload SN‐38 by a pH‐sensitive, cleavable linker. IMMU‐132 specifically binds to Trop‐2, which is broadly expressed in epithelial cancers, gets internalized, and releases the payload SN‐38. SN‐38 is a potent DNA‐damaging agent that targets topoisomerase I and causes double‐stranded DNA breaks that lead to apoptosis. Although IMMU‐132 demonstrated remarkable clinical activity in a phase II multicenter clinical trial, which led to U.S. Food and Drug Administration breakthrough designation of IMMU‐132 as a promising therapeutic agent for metastatic TNBC, the mechanism of action is not fully understood, and both de novo and acquired drug resistance limit efficacy. Accordingly, the overall purpose of our study is (a) to identify emerging biomarkers that may select the patients with metastatic TNBC who would benefit from IMMU‐132 and (b) to recapitulate the intrinsic pathways/targets that synergize with IMMU‐132 to kill TNBC cells. Here we report progress in ongoing studies involving (a) potential biomarkers identified in the profile of serial biopsy TNBC samples from patients who were treated with IMMU‐132 and (b) the synthetic lethal target screening by whole genome CRISPR/Cas9 knockout library in human TNBC cell line models.

Abstract 13 -- LIN28B, a Promoter of Metastasis and Drug Resistance
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LIN28B is an oncofetal RNA binding protein with diverse effects in development, metabolism, and cancer via interactions with let‐7 microRNAs and other RNA targets. Recent work has demonstrated that LIN28B correlates with worsened outcomes in patients with pancreatic ductal adenocarcinoma (PDAC), but the functions of LIN28B in PDAC remain to be elucidated. We hypothesized that LIN28B plays an active role in PDAC metastasis and drug resistance. We knocked LIN28B out of PDAC cell lines utilizing lentiviral transduction of CRISPR guide RNAs and found that the knockout cells had a diminished ability to form nonadherent colonies, migrate, and invade. RNA sequencing of LIN28B‐knockout cells demonstrated multiple signatures, implying a "stressed" cellular phenotype, implying effects on oxidative stress, autophagy, and proteasomal degradation; these stresses partially sensitized the knockout cells to specific cytotoxic pressures. Utilizing a chemical LIN28/let‐7 inhibitor and a let‐7 sponge, an oligonucleotide which binds and degrades let‐7 microRNAs, we found that LIN28B knockout phenotypic effects are partially mediated via de‐repression of let‐7 microRNA species. When placed in animal models of PDAC, the LIN28B‐knockout cells showed a diminished capacity to metastasize. Utilizing a state‐of‐the‐art circulating tumor cell (CTC) microfluidic purification device, we purified CTCs from patients with localized PDAC and found robust expression of LIN28B mRNA in a subset of PDAC CTCs, implicating LIN28B as an important factor in the metastatic cascade. Taken together, LIN28B is linked with multiple aggressive features of PDAC and provides the rationale for further translational investigation into the LIN28B axis as a biomarker and therapeutic target.
